Symphogen
Maria Carlsen Melander has a diverse work experience in the field of research and academia. Maria started their career at Lund University in 2002, where they obtained a PhD in T cell development contributing to autoimmunity. Their research primarily focused on studying the impact of TGF-beta and insulin on T cell development and function.
Following their PhD, Maria joined Rigshospitalet, Copenhagen biocenter in 2009 as a Postdoc at Finsen laboratory. Here, they conducted research on the degradation of extracellular matrix leading to tumor invasion and metastasis. Their particular interest was in studying the collagen receptor Endo-180/uPARAP and setting up in vivo cancer models to study the effect of therapeutic antibody treatment against it.
In 2016, Maria joined Symphogen as a Research Scientist, and later advanced to the role of Senior Research Scientist in February 2020. Their work at Symphogen involves contributing to scientific research and development projects, although specific details on their responsibilities are not provided.
Overall, Maria Carlsen Melander's work experience showcases their expertise in molecular biology, cancer research, and immunology, with a strong focus on understanding and manipulating cellular mechanisms for therapeutic purposes.
Maria Carlsen Melander earned their MSc in Molecular Biology from Lund University in the years 1997 to 2002. Subsequently, they pursued a PhD in Endocrinology (immunology) from the same university from 2002 to 2008.
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.